Evaluation of Patients Treated for the Symptomatic Congenital Cytomegalovirus Infection Semptomatik Konjenital Sitomegalovirüs Enfeksiyonu Nedeniyle Tedavi Edilen Hastaların Değerlendirilmesi
Cocuk Enfeksiyon Dergisi, cilt.16, sa.3, 2022 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 16 Sayı: 3
- Basım Tarihi: 2022
- Doi Numarası: 10.5578/ced.20229752
- Dergi Adı: Cocuk Enfeksiyon Dergisi
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
- Anahtar Kelimeler: Cytomegalovirus infections, ganciclovir, hearing loss, microcephaly, valganciclovir
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: Our current knowledge for the management of symptomatic congenital cytomegalovirus (CMV) infections is limited to few studies. In our study, we aimed to present the data of our patients, who were treated for the diagnosis of symptomatic congenital CMV infections. Material and Methods: A total of 19 patients with the diagnosis of congenital CMV infection treated at our tertiary center hospital between 2015-2021 were retrospectively included in the study. Antiviral treatment (ganciclovir/valganciclovir) was administered to all patients for six months. Results: Five (26.4%) patients were diagnosed with congenital CMV infection within the first three weeks of life. Treatment indications were hearing loss in 12 (63.2%) patients, central nervous system involvement in 7 (36.8%) patients and cholestasis in 6 (31.6%) patients. Six patients had more than one indication. There was no case with eye involvement. Six (31.6 %) patients had pathological findings in cranial imaging and 8 (42.1%) patients had pathological findings in abdominal imaging. Median blood CMV PCR was 1.538 IU/mL (IQR= 850-9.961) and median urine CMV PCR was 425.585 copies/mL (IQR= 111.370-10.105.585). As the side effect of treatment, neutropenia developed in two patients (10.5%). However, no permanent side effect of the treatment was observed. Mean follow-up period was 16.63 ± 8.1 months. Seven (36.8%) patients had chronic sequela of the disease (hearing loss and central nervous system involvement). Conclusion: Ganciclovir/valganciclovir treatment is safe for the treatment of congenital CMV infections.